ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M

ClearPoint Neuro, Inc.

2023-Q1 EPS reported -$0.23 revenue$5,433,000

Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.
Gross margin fell to 59% from 64% due to higher biologics services costs and overhead.
Operating expenses $8.9M vs $7.1M, driven by headcount and stock-based compensation increases.
Cash and short-term investments $31.7M, down from $37.5M; operating cash used $5.7M in quarter.
Reaffirmed full-year 2023 revenue guidance of $25-27M, implying 22-35% YoY growth.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported first quarter ended March 31, 2023 results: revenue $5.4 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $5.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter Highlights • Reported quarterly revenue of $5.4 million, a 8% year-over-year increase; • Increased biologics and drug delivery revenue to $2.7 million, a 24% year-over-year increase; • Announced exclusive multi-year licensing

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.